Hormone Therapy Enhances Tirzepatide Weight Loss in Menopause
The source discusses research indicating that postmenopausal women on hormone therapy (HT) experience significantly greater weight loss when treated with tirzepatide, an obesity medication, compared to those not on HT. This effect mirrors prior findings with semaglutide, another weight-loss drug, suggesting a synergistic interaction where HT enhances the efficacy of these medications in this demographic. […]
HT Amplifies Weight Loss With Tirzepatide in Menopause
Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss is increased with the use of hormone therapy. Medscape Medical News
Menopause Hormone Therapy Boosts GLP-1 Drug Effectiveness, Researchers Say
By Dennis Thompson HealthDay ReporterMONDAY, July 14, 2025 (HealthDay News) — Good news for women of a certain age: Hormone replacement therapy for…
Ozempic for addiction: How an elite rehab center is using GLP-1s to ‘obliterate’ all kinds of cravings
WERNERSVILLE, Pa. — To make sense of the reds and greens dancing across a computer monitor displaying a scale image of a human brain, one requires a vivid vocabulary. At this upscale addiction treatment facility, “neurofeedback therapy” and “quantitative electroencephalogram” are part of the holistic, no-expenses-spared treatment philosophy on offer. But customized brain scans aren’t […]
GLP-1 Therapy Helps Amplify Bariatric Surgery Weight Loss, But Timing Matters
(MedPage Today) — SAN FRANCISCO — In order to maximize weight loss, a GLP-1 receptor agonist may be needed both before and after bariatric surgery, a retrospective analysis found. In 568 patients who underwent bariatric surgery, those who…
More Protein May Help Stave Off Muscle Loss From GLP-1 Treatment
(MedPage Today) — SAN FRANCISCO — Eating more protein may help offset some of the loss of lean mass during semaglutide (Ozempic, Wegovy) treatment, an observational prospective study suggested. After 3 months of treatment, 47.5% of weight…
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society’s annual meeting (ENDO 2025). In […]
Hormone therapy supercharges tirzepatide, unleashing major weight loss after menopause
Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual treatment led to significantly greater weight loss than tirzepatide alone. Women using both treatments lost 17% of their body weight on average, compared to 14% in those not using hormone therapy—and nearly half achieved dramatic 20%+ weight loss.
Tirzepatide: The weight-loss drug that also shrinks breast tumors in mice
In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant weight loss in obese mice but also slashed breast cancer tumor growth. The research, presented at ENDO 2025, links body fat reduction to better cancer outcomes, suggesting that these next-generation weight-loss drugs might offer unexpected benefits beyond metabolic health. With traditional dieting often falling short, this dual-action approach could reshape how doctors tackle obesity-related cancers.